Shanker Dixit, MD
Neurology · Las Vegas, NVNPI 1477558674
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,175 of the $136,625 with a category attached, or 66.0%. AbbVie accounts for 66.7% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2021 at $55,249 and has fallen 81.4% since, to $10,276 in 2025. Among neurology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,706 payments — averaging $80.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$91K
- Merz North America, Inc.$5K
- Johnson & Johnson$4K
- Lundbeck LLC$3K
- Medtronic$3K
- Biogen$3K
- plus $26K from 54 others
Across 139 payments — averaging $8015.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$646K
- Novartis$176K
- Acadia Pharmaceuticals Inc$61K
- EMD Serono, Inc.$52K
- American Regent$44K
- Pfizer$43K
- plus $92K from 9 others
What the payments were for
- Consulting fees$9,5757%
- Speaking & faculty fees$90,17566%
- Travel & lodging$1,9881%
- Food & beverage$34,42625%
- Education$4610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$85,828
- QULIPTA$11,931
- XEOMIN$4,977
- Ponvory$3,520
- Cenobamate$2,100
- Mavenclad$1,600
- VYEPTI$1,500
- PERCEPT PC BRAINSENSE$1,133
- ACTIVA$984
- DYSPORT$515
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$394
- NUPLAZID$285
- Percept$264
- TYSABRI$259
- Vumerity$259
- INGREZZA$170
- SenSight$161
- ONGENTYS$128
- ZEPOSIA$128
- RNS System$125
How this compares
$136,625 in reported general payments places this provider in the 95th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 99 | $1,168,510 |
| BotoxOnabotulinumtoxina | 282 | $372,418 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 105 | $362,052 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 36 | $300,654 |
| VyeptiEptinezumab-Jjmr | 39 | $172,816 |
| UbrelvyUbrogepant | 54 | $55,676 |
| RexultiBrexpiprazole | 13 | $23,699 |
| XcopriCenobamate | 11 | $12,693 |
| VimpatLacosamide | 13 | $11,838 |
| Lacosamide | 21 | $3,587 |
| Oxcarbazepine | 23 | $1,994 |
| Memantine Hcl | 106 | $1,945 |
| Donepezil Hcl | 234 | $1,554 |
| Gabapentin | 213 | $1,436 |
| Duloxetine Hcl | 92 | $992 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam | $282 | $1,168,51099 claims |
| AbbVieBotox, Ubrelvy | $91,063 | $428,094336 claims |
| Grifols USA, LLCGamunex-C | $93 | $362,052105 claims |
| Lundbeck LLCVyepti | $3,106 | $172,81639 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $99 | $23,69913 claims |
| SK Life Science, Inc.Xcopri | $2,872 | $12,69311 claims |
| UCB, Inc.Vimpat | $1,852 | $11,83813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 145 neurology providers in Nevada.
Other neurology in Las Vegas
- Zoltan MariLas Vegas$629K
- Fan ZhangLas Vegas$398K
- le HuaLas Vegas$385K
- Mehdi AnsariniaLas Vegas$306K
- Carrie HershLas Vegas$209K
- Charles KamenLas Vegas$124K
- Toya MaloneLas Vegas$123K
- Nicole TheuvenetLas Vegas$120K
- Kevin XieLas Vegas$46K
- Charles BernickLas Vegas$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.